Could a common cough medicine ingredient soothe eczema?
NCT ID NCT07323719
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a cream containing N-acetyl cysteine (NAC) could improve mild-to-moderate eczema better than plain cold cream. One hundred people with eczema used either the NAC cream or a placebo cold cream. Researchers measured changes in skin bacteria (Staph) and eczema severity scores to see if NAC helps calm the rash and reduce germs.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- N-acetyl cysteine (NAC) 10% in cold cream
- What this could lead to
- If it works, this could offer a new topical option for mild-to-moderate eczema that targets both inflammation and skin bacteria without antibiotics.
- What could go wrong
- This is a small, completed trial with no phase designation. The results may not apply to severe eczema, and NAC cream might not outperform standard treatments or cause skin irritation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
100 people
The number who actually took part.
- Started
-
May 2024
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
2 to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with atopic dermatitis defined according to Hanifin and Rajka criteria, with mild to moderate degree according to EASI score Exclusion Criteria: * -Severe or erythrodermic patients and those indicated for more aggressive systemic immune suppressive therapy. * Patients with oozing or infected lesions * Patients receiving systemic treatment within one month or topical treatment within 2 weeks before enrollment into the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atopic dermatitis (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cairo Unversity
Cairo, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.